Health
Medical Devices
Biotechnology

Emergent BioSolutions

$43.27
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.14 (-0.32%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell EBS and other stocks, options, ETFs, and crypto commission-free!

About

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. Read More Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.

Employees
1,705
Headquarters
Gaithersburg, Maryland
Founded
1998
Market Cap
2.22B
Price-Earnings Ratio
53.31
Dividend Yield
0.00
Average Volume
421.58K
High Today
$44.28
Low Today
$42.97
Open Price
$44.28
Volume
72.05K
52 Week High
$73.89
52 Week Low
$42.29

Collections

Health
Medical Devices
Biotechnology
Biopharmaceutical
Pharmaceutical
Manufacturing
Health And Wellness
Therapy

News

Seeking AlphaMay 20

Emergent Bio's typhoid vaccine OK'd in five new EU states

Emergent BioSolutions (NYSE:EBS) announces that Vivotif (Typhoid Vaccine Live Oral Ty21a) is now approved for sale in France, Portugal, Poland, Czech Republic and Slovakia.

55
Yahoo FinanceMay 20

Emergent BioSolutions to Participate in Series of Investor Conferences

GAITHERSBURG, Md., May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the second quarter of 2019: RBC Capital Markets – 2019 Global Healthcare Conference New York, NY May 21-22, 2019 Goldman Sachs – 40th Annual Global Healthcare Conference (1x1 Meetings Only) Rancho Palos Verdes, CA June 11-13, 2019 Scroll to continue with content Ad Three Part Advisors...

15
Seeking AlphaMay 15

Emergent Bio readies anthrax vaccine shipments into U.S. stockpile

The U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) has notified Emergent BioSolutions (NYSE:EBS) that it will begin procuring its AV7909 anthrax vaccine for delivery into the Strategic National Stockpile.

52

Earnings

-$0.13
$0.27
$0.67
$1.07
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.